PTPN3 and cancer: Our findings reveal that PTPN3 can diminish the sensitivity of certain anti-cancer medications, including paclitaxel, okadaic acid, pipamperone, and tyrothricin while increasing the sensitivity of others, including nelarabine, afatinib, lapatinib, and gefitinib.